Vyne Therapeutics Inc

Vyne Therapeutics Inc (NASDAQ: VYNE) is a pharmaceutical company. It focuses on developing proprietary and differentiated therapies in dermatology.

Investment Highlights – Watch at USD 1.53

• The Company made a loss from operations in Q2 FY2021.
• VYNE is dependent on external funding to run its operation.
• On the profitability front, the EBITDA margin in Q2 FY2021 has been lower than the industry median of 24.0%.
• On the liquidity front, the current ratio in Q2 FY2021 has been lower than the industry median of 2.73x.
• On the leverage front, the debt/equity ratio in Q2 FY2021 has been higher than the industry median of 0.42x.
• From a technical standpoint, the 20-day EMA at about USD 2.39 is sustaining above the stock price. Hence, there could be a correction in the stock price in the near term.

Recent Development 

New licensing: On 12 August 2021, the Company announced licensing of the BET inhibitor platform with In4Derm Ltd. Under this license, VYNE would get exclusive access to new chemical entities.

One Year Share Price Chart

(Source: Refinitiv, Analysis done by Kalkine Group)

Conclusion

Based on its loss-making operations, its dependence on external funding and the poorer profitability, liquidity and leverage position of the Company than the industry, we have given a "WATCH" stance on Vyne Therapeutics Inc at the closing market price of USD 1.53 (as of 18 August 2021).

*The reference data in this report has been partly sourced from Refinitiv.

Disclaimer

References to ‘Kalkine’, ‘we’, ‘our’ and ‘us’ refer to Kalkine Limited.

This website is a service of Kalkine Limited. Kalkine Limited is a private limited company, incorporated in England and Wales with registration number 07903332. Kalkine Limited is authorised and regulated by the Financial Conduct Authority under reference number 579414.

The article has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. No advice or information, whether oral or written, obtained by you from Kalkine or through or from the service shall create any warranty not expressly stated. Kalkine does not intend to exclude any liability which it is not permitted to exclude under applicable law or regulation.

Kalkine does not offer financial advice based upon your personal financial situation or goals, and we shall NOT be held liable for any investment or trading losses you may incur by using the opinions expressed in our publications, market updates, news alerts and corporate profiles. Kalkine does not intend to exclude any liability which it is not permitted to exclude under applicable law or regulation. Kalkine’s non-personalised advice does not in any way endorse or recommend individuals, investment products or services for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a professional authorised financial planner and adviser. You should be aware that the value of any investment and the income from it can go down as well as up and you may not get back the amount invested.